Bayer sees new med Kovaltry as just one piece of its hemophilia puzzle

Earlier this week, Bayer nabbed an EU approval for a new, longer-lasting hemophilia med, Kovaltry. But the company isn't expecting all of the patients on stalwart treatment Kogenate to jump ship for the newcomer--which is why it thinks it's important to offer both. "It's not a market where you see the kind of adoption rates you see in oncology," Hansjoerg Duerr, Bayer Hematology's head of global strategic marketing, told FiercePharmaMarketing in an interview at the J.P. Morgan Healthcare Conference in January. "If people are very satisfied with their current product, it's a step into the unknown." More from FiercePharmaMarketing

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.